Business Wire

GCCA

Share
2021 “Concrete in Life” Global Photography Competition Launches – Focus on Sustainability, Beauty and Versatility of Concrete

The third annual GCCA “Concrete in Life” photography competition has today launched with a call for amateur and professional photographers from around the world to capture the role of concrete in their lives and its role in the sustainable world of tomorrow.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005132/en/

Concrete plays a key role in supporting society around the world. Its durability, strength, resilience and boundless versatility means it can be used for nearly any application, while its properties such as thermal mass, recyclability and carbon uptake make it the most sustainable building material.

Judges include Isabel Allen, Editor at Architecture Today, Gian Luca Barone from Zaha Hadid Architects and experts from the Global Cement and Concrete Association (GCCA). They will be looking for entries showing concrete contributing to their individual lives and wider society, and notably sustainable buildings and infrastructure, to inspire the public in the run up to COP26, as the GCCA prepares to announce its detailed roadmap to zero carbon concrete.

Contestants are invited to capture imagery in the following categories, which include a brand new Sustainable Concrete category:

  • Urban design and use – images of the city landscapes and buildings around us, both well-known and hidden away
  • Infrastructure – photographs of our infrastructure, in our cities and rural, above and below ground
  • Concrete in daily life – the human side of concrete and how it’s used and interacted with daily
  • Sustainable Concrete – how concrete is used in sustainable construction, buildings and infrastructure such as wind farms, dams, green overpasses, wildlife crossings, green buildings

The competition crown one winner for the professional and amateur brackets of each category as well as one overall winner for the “Best Concrete in Life” photo of the year from the eight finalists. Each category winner will receive $2,500 in prize money, while the overall winner will receive $10,000.

Thomas Guillot, GCCA Chief Executive, said: “Being the world’s most used human-made product, concrete provides the foundation for so many lives. The competition is designed to capture that importance and demonstrate its versatility throughout society. Entries to the first two ‘Concrete in Life’ competitions from both professionals and amateurs were exceptional and managed to capture concrete’s strength, durability and resilience, and we’re so excited to be launching the third annual competition. We look forward to receiving a wide array of unique and inspiring entries from all over the world.”

The annual competition by the GCCA attracts tens of thousands of entries from professional and amateur photographers and challenges participants to capture photos that highlight the beauty of concrete and the vital role it plays in our society.

To enter the competition, participants should post a picture that they’ve taken on Instagram or Twitter using the hashtags #ConcreteInLife2021, #UrbanConcrete, #ConcreteInfrastructure, #ConcreteInDailyLife, and #SustainableConcrete. They should also tag the GCCA – @the.gcca on Instagram or @theGCCA on Twitter.

Winners will also be invited to speak about their images with the GCCA, with their images shared on GCCA’s website and social media channels.

Judging the entries are:

  • Gian Luca Barone, Senior Associate, Zaha Hadid Architects
  • John Fairley, Design Director, Curious Productions
  • Thomas Guillot, GCCA Chief Executive
  • Isabel Allen, Editor, Architecture Today

The competition will run until October 22nd 2021, with the winners announced during January 2022. Full competition details can be found at https://gccassociation.org/concreteinlife2021/

-ends-

About the GCCA:

Launched in January 2018, the Global Cement and Concrete Association (GCCA) is dedicated to developing and strengthening the sector’s contribution to sustainable construction.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye